Thymosin alpha-1 (Tα1) is a 28-residue peptide, acetylated at its N-terminus, that was first purified from calf thymus extracts. It turned out to be a fragment of a larger, widely expressed protein, prothymosin α, rather than a thymus-specific hormone, but the original name stayed. Tα1 is one of the most extensively reviewed thymic peptides in immunology.
Interest in Tα1 comes from its proposed role as a regulator of immune signaling, studied in cultured immune cells and in animal models of infection and tumor immunology. The overview below traces the peptide from thymus extracts to synthesis, summarizes the receptor and cell-signaling research, describes the main models, and lays out the limitations of the evidence.
At a glance
- Class: 28-amino-acid acetylated peptide derived from prothymosin α
- Origin: Isolated in the 1970s from thymosin fraction 5, a calf thymus extract studied by Allan Goldstein’s group (Garaci, 2007)
- Structure: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH; C129H215N33O55; 3108.3 g/mol; CAS 62304-98-7
- Main research areas: innate immune receptor signaling, dendritic cell and T-cell biology, infection and tumor models, age-related thymic changes
- Regulatory status: Not FDA approved; a synthetic form (thymalfasin) is approved in a number of other countries; the material sold here is a research reagent
Structure and origin
In the 1960s and 1970s, Goldstein and colleagues prepared a partially purified calf thymus extract, thymosin fraction 5, and separated it into dozens of peptides. Each was named by its position on an isoelectric focusing gel: alpha peptides were acidic, beta peptides more neutral. Tα1 was the first of these to be sequenced and later produced by chemical synthesis, which removed the need for tissue extraction (Garaci, 2007).
The peptide is strongly acidic. Its 28 residues include many glutamate and aspartate side chains, giving it a large net negative charge at neutral pH, and it has no cysteines or disulfide bonds. Its precursor, prothymosin α, is a 113-residue nuclear protein found in many cell types, and Tα1 corresponds to its N-terminal region. How, and how much, free Tα1 is released from the precursor in tissues is still discussed in reviews (Dominari et al., 2020).
Mechanism: what the research shows
For decades Tα1 was described mainly by its effects on immune cells in culture, without a defined receptor. A shift came in the 2000s, when work on mouse and human dendritic cells linked Tα1 to toll-like receptor (TLR) signaling. TLRs are pattern-recognition receptors on antigen-presenting cells; reviews describe Tα1 as acting through TLR9 and TLR2 in myeloid and plasmacytoid dendritic cells, with downstream NF-κB activation and cytokine production (Goldstein et al., 2009).
Through these innate-immune pathways, Tα1 is thought to influence how dendritic cells instruct T cells, including the balance between T-helper subsets and regulatory T cells. Garaci’s historical overview and later reviews describe this model as a bridge between innate sensing and adaptive immunity, while noting that many details come from individual laboratories and from specific infection models (Garaci, 2007; Dominari et al., 2020).
Studies differ widely in species, cell type, peptide source and concentration, and reported effects range from activation to dampening of immune responses depending on the model. That context dependence is one reason the TLR framework is best treated as the leading working hypothesis rather than a settled mechanism.
Key areas of study
Dendritic cell and TLR signaling
Cultured dendritic cells and TLR reporter systems are the core in-vitro tools. Readouts include maturation markers, cytokine secretion and the downstream transcription factors activated after exposure (Goldstein et al., 2009).
T-cell biology
Tα1 was first characterized in assays of T-cell maturation and function using thymus-derived cells and immunodeficient animal models. Later studies examined cytokine profiles and helper-subset differentiation in culture (Garaci, 2007).
Infection and tumor models
Animal models of viral and fungal infection and of tumor immunology have used Tα1, often in combination with other immune-modulating agents or chemotherapy, to examine changes in immune-cell populations and cytokine signaling (Dominari et al., 2020).
Thymic involution and immune aging
The thymus shrinks with age, and Tα1 is used in research on how that involution relates to changes in immune-cell populations. A 2025 review collects the experimental work on Tα1 in this context (Simonova et al., 2025). These are model findings about immune biology, not evidence of any effect in people.
What the evidence does not show
- Mechanistic data come from cell culture and animal models. They do not establish immune effects in humans from any research-grade material.
- Older studies often used thymosin fraction 5, a mixture of many peptides, or prothymosin α rather than purified synthetic Tα1. Results from these preparations cannot be attributed to Tα1 alone.
- A dedicated, high-affinity receptor for Tα1 has not been structurally defined; the TLR model rests on functional studies.
- Clinical studies of thymalfasin in various countries involved a specific pharmaceutical product, and their findings are not transferable to research reagents.
- Much of the review literature comes from groups closely involved in the peptide’s development, and independent replication of some mechanistic claims is limited.
Regulatory status
Thymosin alpha-1 is not approved by the FDA. A synthetic form, thymalfasin, is approved as a prescription drug in a number of countries outside the United States and has been evaluated in clinical studies. The material sold by Rogue Compounds is a research reagent, not that drug product, and is not for human use.
Handling and storage in the lab
Lyophilized thymosin alpha-1 should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light.
Sourcing and documentation
Rogue Compounds has Thymosin Alpha-1 made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same batch COA is on the product page and in the COA Library.
View Thymosin Alpha-1 on Rogue Compounds
References
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. PMID 17567941
- Goldstein AL, et al. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608. PMID 19392576
- Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature. World J Virol. 2020;9(5):67-78. PMID 33362999
- Simonova MA, et al. Aging and thymosin alpha-1. Int J Mol Sci. 2025;26(23):11470. PMID 41373628
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.